A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

PURPOSE: This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in patients with advanced malignancies. METHODS: We conducted a fixed-sequence, single-blind, placebo-controlled study. Patients (n = 23) received...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony
Формат: Artigo
Язык:Inglês
Опубликовано: Springer-Verlag 2012
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3456920/
https://ncbi.nlm.nih.gov/pubmed/22878520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1942-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы